Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Dec 16, 2024 10:01am
62 Views
Post# 36363962

RE:New Press Release - StageZero Life Sciences, Ltd Announces Q3 2024 Financial Results and Operational Update

RE:New Press Release - StageZero Life Sciences, Ltd Announces Q3 2024 Financial Results and Operational UpdateQ3 revenue of 500k with a loss of 399k versus Q2 revenue of 390k with a loss of 650k.  So revenues are ticking up and losses moving down due to cost cutting, smaller lab and less people.  

Can't save your way to the bottom line they need revenues to more than double. 

They now mention paying the auditors within the next 2 weeks but the said on Oct 1 it would be Oct 31 so how many times they gonna keep moving the goal posts.  Assuming they can come up with an equity arrangement (likely Riggs again) and put this behind them to pay the auditors and relist in the new year they will soon be needing to pay the auditors again to complete 2024 year end.

Still and always it comes down to being able to sell Aristotle.  $2 million in overall revenues if they continue at this pace (500k per quarter) with $1.6 million in losses is not sustainable.  They have operating costs about as low as they can go.  Now its time to see if the partnerships can drive Aristotle otherwise they will soon be in the same boat of not being able to file 2024 year end.

And once again where are the partnership announcements we were told were just days away in October?  

This was from October 1st news of Q2:

New partnerships have been brought on, which will increase the access to the Company’s Aristotle test. The launch of these partnerships will be announced by the Company in the coming days. Additional partnerships and the growth of the uptake of the Aristotle test will be a strong focus over the coming months. The Company anticipates additional partnerships and will announce them as they launch.



 
<< Previous
Bullboard Posts
Next >>